Publication: Dispositivos de seguridad en el reenvasado de medicamentos para el comercio paralelo : apuntes sobre tres sentencias del Tribunal de Justicia de la Unión Europea.
Loading...
Date
2023
Authors
Fernández Domínguez, Juan José
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia, Servicio de Publicaciones.
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
La normativa de la Unión Europea destinada a evitar la entrada de medicamentos falsificados en la cadena de suministros legal, al tiempo que proporciona una interesante regulación uniforme sobre los dispositivos de seguridad que han de figurar en sus envases, ha modulado de manera sustancial la primera de las condiciones (“requisitos BMS”) exigidos por la jurisprudencia europea para el reetiquetado o reenvasado con miras a la importación paralela. En particular, ha proporcionado continuidad a la saga de pronunciamientos en torno a si existe o no agotamiento de marca y, por ende, si es objetivamente necesario un embalaje distinto con nuevos identificadores único o, por el contrario, existen otras medidas menos perjudiciales para el titular de la marca que puedan adoptar las empresas dedicadas a la importación.
EU legislation aimed at preventing the entry of counterfeit medicines into the legal supply chain, while providing an interesting uniform regulation on the safety features to be included on their packaging, has substantially modified the first of the conditions ("BMS requirements") required by European jurisprudence for repackaging or relabelling for parallel importation. In particular, it has provided continuity to the saga of rulings on whether or not there is exhaustion of trade marks and, therefore, whether different packaging with a new unique identifier is necessary from an objective point of view or, on the other hand, there are other measures less damaging to the trade mark owner that can be taken by the importing companies.
EU legislation aimed at preventing the entry of counterfeit medicines into the legal supply chain, while providing an interesting uniform regulation on the safety features to be included on their packaging, has substantially modified the first of the conditions ("BMS requirements") required by European jurisprudence for repackaging or relabelling for parallel importation. In particular, it has provided continuity to the saga of rulings on whether or not there is exhaustion of trade marks and, therefore, whether different packaging with a new unique identifier is necessary from an objective point of view or, on the other hand, there are other measures less damaging to the trade mark owner that can be taken by the importing companies.
publication.page.subject
Citation
Anales de Derecho, V. 40, N. 2, 2023, p. 49-84
item.page.embargo
Collections
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/